Hangzhou Tigermed Consulting Co Ltd
300347
Company Profile
Business description
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's offered services include bioanalytical, medical writing, biostatistical analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Contact
Block 8, No. 19 Jugong Road
Room 2001-2010, 20th Floor
Xixing Sub-District, Binjiang District
Hangzhou310053
CHNT: +86 57128887227
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
10,251
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,265.41 | 3.25 | 0.04% |
| DAX 40 | 24,635.40 | 144.34 | 0.59% |
| Dow JONES (US) | 49,709.54 | 800.82 | 1.64% |
| FTSE 100 | 10,354.51 | 45.29 | 0.44% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 22,722.14 | 181.55 | 0.81% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,869.73 | 71.33 | 1.05% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |